Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.

Reed W, Noga SJ, Gee AP, Rooney CM, Wagner JE, McCullough J, McKenna DH, Whiteside TL, Donnenberg AD, Baker AK, Lindblad RW, Wagner EL, Mondoro TH.

Transfusion. 2009 Apr;49(4):786-96. doi: 10.1111/j.1537-2995.2008.02027.x. Epub 2008 Dec 23. Review.

2.

An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.

Wood D, Wesselschmidt R, Hematti P, Gee AP, Rooney C, Silberstein L, Armant M, Couture L, Wagner JE, McKenna DH Jr, Hei D, Mondoro TH, Welniak L, Lindblad R.

Clin Transl Sci. 2014 Apr;7(2):93-9. doi: 10.1111/cts.12148. Epub 2014 Mar 21. No abstract available.

3.

Cellular Therapies Clinical Research Roadmap: lessons learned on how to move a cellular therapy into a clinical trial.

Ouseph S, Tappitake D, Armant M, Wesselschmidt R, Derecho I, Draxler R, Wood D, Centanni JM.

Cytotherapy. 2015 Apr;17(4):339-43. doi: 10.1016/j.jcyt.2014.10.008. Epub 2014 Dec 4.

4.

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, Hare JM, Hei DJ, Hoffman AM, Kourembanas S, McKenna DH, Ortiz LA, Ott HC, Tente W, Thébaud B, Trapnell BC, Weiss DJ, Yuan JX, Blaisdell CJ.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):370-5. doi: 10.1164/rccm.201303-0522WS. Review.

5.

Shipping of therapeutic somatic cell products.

Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, Gee A, Durett A, Lindblad R, Wood D, Styers D.

Cytotherapy. 2011 Feb;13(2):201-13. doi: 10.3109/14653249.2010.506507. Epub 2010 Aug 26.

PMID:
20795760
6.

Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.

Lindblad RW, Ibenana L, Wagner JE, McKenna DH Jr, Hei DJ, Hematti P, Couture LA, Silberstein LE, Armant M, Rooney CM, Gee AP, Welniak LA, Heath Mondoro T, Wood DA, Styers D.

Transfusion. 2015 Mar;55(3):674-9. doi: 10.1111/trf.12881. Epub 2014 Oct 14. Review. No abstract available.

7.

Providing Contemporary Access to Historical Biospecimen Collections: Development of the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).

Giffen CA, Carroll LE, Adams JT, Brennan SP, Coady SA, Wagner EL.

Biopreserv Biobank. 2015 Aug;13(4):271-9. doi: 10.1089/bio.2014.0050. Epub 2015 Jul 17.

8.

Developments in clinical cell therapy.

Stroncek D, Berlyne D, Fox B, Gee A, Heimfeld S, Lindblad R, Loper K, McKenna D Jr, Rooney C, Sabatino M, Wagner E, Whiteside T, Wood D, Heath-Mondoro T.

Cytotherapy. 2010 May;12(3):425-8. doi: 10.3109/14653240903511952.

9.

A training program in cardiovascular cell-based therapy: from the NHLBI Cardiovascular Cell Therapy Research Network.

Petersen JW, Winchester DE, Park K, Szady AD, Della Rocca DG, Ahmed M, Tassin H, Qi Y, Pepine CJ.

Regen Med. 2014;9(6):793-7. doi: 10.2217/rme.14.57.

11.

A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products.

Gee AP, Sumstad D, Stanson J, Watson P, Proctor J, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R.

Cytotherapy. 2008;10(4):427-35. doi: 10.1080/14653240802075476.

12.

Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.

Lefer DJ, Bolli R.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):332-9. doi: 10.1177/1074248411414155.

PMID:
21821536
13.

An official American Thoracic Society workshop report: stem cells and cell therapies in lung biology and diseases.

Weiss DJ, Chambers D, Giangreco A, Keating A, Kotton D, Lelkes PI, Wagner DE, Prockop DJ; ATS Subcommittee on Stem Cells and Cell Therapies..

Ann Am Thorac Soc. 2015 Apr;12(4):S79-97. doi: 10.1513/AnnalsATS.201502-086ST.

PMID:
25897748
14.

NHLBI plans for the promise of cell-based therapies.

Mondoro TH, Thomas JW, Henslee-Downey PJ, Peterson CM.

Cytotherapy. 2005;7(4):317-27.

PMID:
16162453
15.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
16.

Notes from the Director, National Heart, Lung, and Blood Institute: transitions.

Nabel EG.

Blood. 2009 Mar 26;113(13):2875-7. doi: 10.1182/blood-2008-12-194100.

17.

Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community.

Tarantal AF, Skarlatos SI.

Hum Gene Ther. 2012 Nov;23(11):1130-5. doi: 10.1089/hum.2012.178. Epub 2012 Oct 19. Review.

18.

Evidence Brief: Effectiveness of Intensive Primary Care Programs.

Peterson K, Helfand M, Humphrey L, Christensen V, Carson S.

VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2013 Feb.

19.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
20.

Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).

Simari RD, Moyé LA, Skarlatos SI, Ellis SG, Zhao DX, Willerson JT, Henry TD, Pepine CJ.

J Cardiovasc Transl Res. 2010 Feb;3(1):30-6. doi: 10.1007/s12265-009-9160-3.

Supplemental Content

Support Center